Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Valued at $11.64 billion, Jazz Pharmaceuticals (JAZZ) is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. It derives most of its revenues from its sleep disorder drugs Xywav and Xyrem. Both drugs are approved for treating cataplexy and excessive daytime sleepiness in narcolepsy patients. 

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation....

Fundamentals

See More
  • Market Capitalization, $K 11,246,396
  • Shares Outstanding, K 61,560
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 224 M
  • EBITDA $ 921 M
  • 60-Month Beta 0.22
  • Price/Sales 2.73
  • Price/Cash Flow 11.63
  • Price/Book 2.66

Options Overview Details

View History
  • Implied Volatility 39.92% (+0.49%)
  • Historical Volatility 43.28%
  • IV Percentile 57%
  • IV Rank 32.23%
  • IV High 69.53% on 08/05/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 17) 9.60 (5.24%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 129
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 6,692
  • Open Int (30-Day) 11,329
  • Expected Range 173.55 to 192.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.98
  • Number of Estimates 5
  • High Estimate 4.62
  • Low Estimate 3.14
  • Prior Year 0.60
  • Growth Rate Est. (year over year) +563.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
176.67 +3.67%
on 03/06/26
191.54 -4.38%
on 03/02/26
-6.87 (-3.62%)
since 02/27/26
3-Month
156.95 +16.69%
on 01/08/26
198.00 -7.50%
on 02/26/26
+12.67 (+7.43%)
since 12/26/25
52-Week
95.49 +91.80%
on 04/09/25
198.00 -7.50%
on 02/26/26
+60.23 (+49.00%)
since 03/28/25

Most Recent Stories

More News
Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains...

JAZZ : 183.15 (+0.25%)
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness

JAZZ : 183.15 (+0.25%)
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026

Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally...

JAZZ : 183.15 (+0.25%)
1 Value Stock to Research Further and 2 We Ignore

1 Value Stock to Research Further and 2 We Ignore

PUBM : 8.12 (-0.85%)
JAZZ : 183.15 (+0.25%)
G : 37.45 (+2.38%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

COLL : 31.99 (-1.39%)
JAZZ : 183.15 (+0.25%)
BDX : 154.69 (+0.12%)
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

JAZZ : 183.15 (+0.25%)
Jazz: Q4 Earnings Snapshot

Jazz: Q4 Earnings Snapshot

JAZZ : 183.15 (+0.25%)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

JAZZ : 183.15 (+0.25%)
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –

JAZZ : 183.15 (+0.25%)
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

JAZZ : 183.15 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 187.52
2nd Resistance Point 186.18
1st Resistance Point 184.66
Last Price 183.15
1st Support Level 181.81
2nd Support Level 180.47
3rd Support Level 178.96

See More

52-Week High 198.00
Last Price 183.15
Fibonacci 61.8% 158.84
Fibonacci 50% 146.74
Fibonacci 38.2% 134.65
52-Week Low 95.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.